The future of cancer treatment lies in targeted and precise therapies. SHINE’s No-Carrier-Added Lutetium-177 (n.c.a. Lu-177) ILUMIRA represents the powerful technology driving this future.
When paired with a cancer-seeking molecule, ILUMIRA offers a new level of precision in the fight against cancer. Its radioactive properties allow it to accurately target tumor cells while sparing healthy tissue, making therapies more effective, safer, and more patient-friendly.
Through an intelligent carrier molecule, the isotope is delivered directly to the tumor and its metastases. Once localized, the isotope emits short-range radiation that selectively destroys cancer cells. This approach provides a more targeted and gentler therapy option, making a meaningful difference in cancer care worldwide.
N.C.A. Lu-177 is produced at SHINE’s U.S. facility in compliance with current Good Manufacturing Practices (cGMP). It also meets and even exceeds all European Pharmacopoeia monograph requirements for lutetium. In 2022, a formal Drug Master File (DMF) was submitted to the U.S. Food and Drug Administration (FDA).
